Royal Peptides
Royal Peptides supplies research compounds to qualified adults for in-vitro laboratory use. Confirm both requirements to enter.
Royal Peptides is only for adults 21+ buying for laboratory research.
Leave this site
Royal Peptides products are offered exclusively for laboratory research, analytical and scientific applications. Not for human or veterinary use.
Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.
Research onlyLaboratory materialAnalytical use
Where applicable, Royal Peptides research materials are supplied in lyophilized form. Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.
Storage requirements may vary by compound, formulation and production lot. Refer to the product label and available product-specific documentation.
Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning and external packaging.
Third-party verified CBL-514 · 20 mg lyophilized · ≥99% purity by HPLC, identity confirmed by mass spectrometry · Lot RPCBL1 with certificate of analysis included. The first-in-class adipocyte-apoptosis compound behind two FDA-cleared Phase 3 programs. For laboratory research use only.
Research noticeFor laboratory and research purposes only. Not intended for human consumption, diagnostic or therapeutic use, or administration to humans or animals.
CBL-514 is a first-in-class, injectable small-molecule compound that triggers apoptosis — programmed cell death — in fat cells. Developed by Caliway Biopharmaceuticals, it works by inhibiting the kinase DYRK1B, which raises Caspase-3 and the Bax/Bcl-2 ratio. It has completed multiple Phase 2 studies and is now in two FDA-cleared global Phase 3 trials for abdominal subcutaneous fat reduction, with results expected in 2027. It is not approved for human use.
| Compound name | CBL-514 (also written CBL514, CBL 514) |
|---|---|
| Compound class | Small molecule (not a peptide) |
| Originator | Caliway Biopharmaceuticals (Taiwan) |
| Molecular target | DYRK1B inhibition → ↑ Caspase-3, ↑ Bax/Bcl-2 ratio |
| Primary research area | Localized subcutaneous adipose reduction; also studied in cellulite, Dercum’s disease and lipoma models |
| Mechanism type | Apoptosis (programmed cell death), as opposed to necrosis |
| Clinical stage | Phase 3 — SUPREME-01 (CBL-0301, NCT07140939) and SUPREME-02 (CBL-0302) |
| Regulatory status | Investigational. Not FDA approved. EMA orphan designation for Dercum’s disease. |
| Royal Peptides spec | ≥99% HPLC · MS identity confirmed · 20 mg lyophilized · Lot RPCBL1 |
| Storage | −20 °C, sealed, dark, dry |
Most metabolic research compounds — including GLP-1 and GIP receptor agonists — shrink adipocytes by changing energy balance. CBL-514 is studied for a different endpoint: reducing adipocyte number in a localized area.
In preclinical and clinical work, CBL-514 has been shown to induce adipocyte apoptosis by inhibiting DYRK1B. Apoptotic cells shrink and fragment internally while keeping their membranes intact, which is why researchers distinguish it from necrotic agents that rupture cells and drive local inflammation.
Caliway has presented preclinical data in diet-induced obese rats combining CBL-514 with tirzepatide, reporting enhanced weight loss and reduced weight regain. A 120-subject Phase 2 combination study (CBL-0201WR) has been cleared by the FDA.
CBL-514 has one of the deepest data packages of any compound in the localized-fat category. Caliway reports that 10 completed clinical trials involving 544 subjects met their efficacy and safety endpoints.
A randomized Phase 2b trial of 108 adults with moderate-to-severe abdominal fat — up to four treatments, three weeks apart — was published in Aesthetic Surgery Journal in May 2026, using clinician- and patient-reported outcomes plus MRI.
In the separate Dercum’s disease Phase 2 study, CBL-514 met its primary pain-reduction endpoint (3.1 vs 1.9 points for placebo, p = 0.005), with no drug-related serious adverse events reported. Injection-site reactions were the most common tolerability finding and were graded mild to moderate.
Randomized, placebo-controlled abdominal study across the US and Australia.
Granted for Dercum’s disease.
Both met primary endpoints. FDA clears SUPREME-01 (CBL-0301) Phase 3 in July.
Preclinical CBL-514 + GLP-1 combination data in obese rat models.
~320-participant Phase 3 in the US, Canada and Australia, with MRI fat-volume endpoint. Phase 2b published in Aesthet Surg J.
Results from both pivotal trials anticipated.
Researchers selecting a compound for adipose studies usually weigh these three mechanisms. Here’s how they differ at the level of the cell.
| Attribute | CBL-514 | Deoxycholic acid (ATX-101) | GLP-1 / GIP agonists |
|---|---|---|---|
| Molecule type | Small molecule | Bile acid | Peptide |
| Mode of action | Apoptosis via DYRK1B | Membrane lysis (necrosis) | Appetite & energy intake |
| Effect on adipocytes | Reduces cell number | Destroys cells non-selectively | Reduces cell size |
| Scope | Localized, large-area studies | Small areas (submental) | Systemic |
| Inflammatory profile | Low (apoptotic) | Higher (necrotic) | Not applicable |
| Status | Phase 3, investigational | Approved (submental) | Approved (various) |
Novel compounds attract unreliable suppliers. Our process is built so you never have to wonder what’s in the vial.
Independent lab testing
Every lot is analysed by a third-party lab — never in-house only.
HPLC purity
Chromatogram published for each lot, ≥99% threshold.
MS identity
Mass spectrometry confirms you received CBL-514, not a substitute.
Cold-chain handling
Stored at −20 °C and shipped insulated to protect stability.
Lyophilized CBL-514 should be stored at −20 °C in its sealed vial, protected from light and humidity. Allow the vial to equilibrate to room temperature before opening to prevent condensation on the powder.
Reconstitution solvent and concentration should follow your laboratory’s validated protocol and the solubility information on the lot COA. Aliquot reconstituted material to avoid repeated freeze–thaw cycles.
| Vial | 1 × 20 mg CBL-514, lyophilized, sealed |
|---|---|
| Documentation | Printed lot COA with QR link to full report |
| Packaging | Insulated, unbranded outer carton |
| Labelling | “For research use only. Not for human consumption.” |
CBL-514 is a first-in-class small-molecule compound developed by Caliway Biopharmaceuticals that induces apoptosis (programmed cell death) in fat cells. Its proposed mechanism is inhibition of DYRK1B, which raises Caspase-3 expression and the Bax/Bcl-2 ratio. It is currently in Phase 3 clinical trials for abdominal subcutaneous fat reduction.
No. Despite often being discussed alongside research peptides, CBL-514 is a small molecule, not a peptide chain. This affects its handling, solubility and analytical testing.
No. CBL-514 is an investigational compound. The FDA cleared two pivotal Phase 3 studies (SUPREME-01 / CBL-0301 and SUPREME-02 / CBL-0302), with results expected in 2027. It is not approved for any human use. Royal Peptides supplies it strictly for laboratory research.
Deoxycholic acid is a detergent-like agent that lyses fat cells by disrupting membranes (necrosis), which is associated with inflammation. CBL-514 is reported to work through apoptosis, a controlled cell-death pathway, which researchers are studying because it may spare surrounding tissue.
Every lot is tested by an independent third-party laboratory using HPLC for purity and mass spectrometry for identity. The lot-specific certificate of analysis is available on this page and ships with each order.
Store lyophilized CBL-514 at −20 °C, sealed and protected from light and moisture. Allow the vial to reach room temperature before opening to prevent condensation.
Last reviewed: October 31, 2026 · Royal Peptides research team
Independent lab results for each lot. Match the lot number on your vial to its report.
View CBL-514 COAs →Orders placed before the daily cut-off ship the same business day when in stock, in plain, secure packaging with tracking.
Store unopened vials frozen (−20 °C), protected from light and moisture. Follow the storage conditions on the product label and the batch COA.
